My take after some DD. “Any thoughts regarding
My take after some DD. “Any thoughts regarding yesterday's ruling in the Federal Circuit Court of Appeals regarding SFOR Technologies vs Secure Authority, in which the 3 judge panel ruled "Affirmed", based on Rule 36?” I will start that I am not an attorney that being said there seems to be a mistake. The appellate judges should have served us an opinion as a matter of due process. Though the court can rule based on 36 they should have attached their opinion unless we have fundamental mistakes that are outlined in the rule. In this case they can issue “affirmed” without an opinion. From what I have read the court should have issued their opinion to offer why our Appeal was not correct and the California judge was initially correct and SA was not violating our patent. I personally feel that we have a violation of rights for a second appeal that ZPaul has showed us already in docket. I am guessing we have some but few courses we can take on the case. 1) file the appeal based off of due process according to our rights based of our confirmed status. 2) talk to our legal council to see if we made any simple mistakes that warranted the no response action. 3) negotiate a settlement to stop all further action against SA. My guess is SA was probably elated by the response but there is a fundamental problem in that there is no opinion.. That cause concern for all parties as it gives no finality! I would think both parties would talk about this as a reasonable possibility to settle now as the court violated the rights of SFOR. I don’t see any other outcomes that are real and SA gets off cheap by terms of what should have happened.or what is fair. It also creates issue back to DUO as no opinion leaves it open ended with their deal even though they were happy as well from the decision. ( No opinion causes a delima.) I see that if we force the judges to write an opinion we would be shooting ourselves in the foot as they clearly do not understand our logic, or the hard core facts in our case that could be explained a little easier if it had to be. Enough to overturn their initial ruling? No in my humble opinion as egos are on the line that they ruled incorrectly! We have to go up the chain from what I have read and 5.6 percent of theses cases are heard from the Supreme Court. Do I think we have a shot? Yes. I think we have an opportunity but I see the Supreme Court as last resort and way more money than our financed legal team would want to take on. So I am waiting to see what tam SFOR does here as our Legal team has to regroup with options. I am betting that no information out of anyone at SFOR is prudent as no direction can be had until they know their rights to this bombastic ruling with no opinion. My few thoughts for Today. Peace Bear.
6
Zerify Inc (ZRFY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...
Continue Reading
Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...
Continue Reading
Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...
Continue Reading
What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...
Continue Reading
Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...
Continue Reading
An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...
Continue Reading
Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...
Continue Reading
Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...
Continue Reading
IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...
Continue Reading
Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...
Continue Reading
Top 5 Most Recently Viewed Articles
Dorman Products, Inc. Prepares for Upcoming Financial Reporting Dorman Products, Inc. (NASDAQ: DORM) is gearing up to share its financial results for the fourth quarter and full year that concluded on December 31, 2024. This exciting announcement highlights Dorman's ongoing commitment to transparency and investor engagement. Financial Announcement Details The firm is set...
Continue Reading
Couple Takes Charge of New PostalAnnex Venture as Franchisees Annex Brands, Inc. is excited to announce the opening of its new PostalAnnex store under the ownership of Vino and Reha Veer. This newest location represents a significant addition to the company's growing footprint in the packing, shipping, and office services sector. Offering Comprehensive Services for the...
Continue Reading
Baltic Horizon Fund Announces New Interest Rate for Bonds Baltic Horizon Fund has recently revealed the interest rate for its 5-year bonds (ISIN: EE3300003235) for the upcoming interest period, set to begin shortly. This new rate reflects a competitive edge in the current financial landscape. The bonds will carry an annual interest rate of 10.151%, which combines a base...
Continue Reading
Telix Pharmaceuticals Acquires Next-Generation Therapeutics Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX) has recently completed a significant acquisition aimed at enhancing its therapeutic offerings. This strategic move involves obtaining a next-generation pipeline of therapeutic candidates, along with an innovative biologics technology platform developed by the...
Continue Reading
Overview of SLB's Russian Assets As we enter 2024, SLB, a leading oilfield services company, has disclosed that its net assets in Russia remain valued at approximately $600 million, unchanged from the previous year. This steady valuation is notable in light of the recent pressures faced by companies operating in the region. Challenges in the Russian Market Despite the...
Continue Reading
